Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours ; volume:73 ; number:5 ; day:30 ; month:3 ; year:2024 ; pages:1-9 ; date:5.2024
Cancer immunology immunotherapy ; 73, Heft 5 (30.3.2024), 1-9, 5.2024
- Urheber
-
Patel, Manish R.
Johnson, Melissa
Winer, Ira
Arkenau, Hendrik-Tobias
Cook, Natalie
Samouëlian, Vanessa
Aljumaily, Raid
Kitano, Shigehisa
Duffy, Christine
Ge, Miaomiao
Elgadi, Mabrouk
Siu, Lillian L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-024-03654-0
- URN
-
urn:nbn:de:101:1-2407090921472.159479825476
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Patel, Manish R.
- Johnson, Melissa
- Winer, Ira
- Arkenau, Hendrik-Tobias
- Cook, Natalie
- Samouëlian, Vanessa
- Aljumaily, Raid
- Kitano, Shigehisa
- Duffy, Christine
- Ge, Miaomiao
- Elgadi, Mabrouk
- Siu, Lillian L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models